Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Foghorn Therapeutics (FHTX) over the last 4 years, with Q2 2025 value amounting to -$8000.0.

  • Foghorn Therapeutics' Gains from Investment Securities fell 10113.48% to -$8000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 2568.53%. This contributed to the annual value of $860000.0 for FY2024, which is 7578.15% down from last year.
  • Foghorn Therapeutics' Gains from Investment Securities amounted to -$8000.0 in Q2 2025, which was down 10113.48% from $1.2 million recorded in Q1 2025.
  • Over the past 5 years, Foghorn Therapeutics' Gains from Investment Securities peaked at $1.7 million during Q2 2023, and registered a low of -$8000.0 during Q2 2025.
  • For the 3-year period, Foghorn Therapeutics' Gains from Investment Securities averaged around $623444.4, with its median value being $705000.0 (2024).
  • Examining YoY changes over the last 5 years, Foghorn Therapeutics' Gains from Investment Securities showed a top increase of 236530.61% in 2025 and a maximum decrease of 10113.48% in 2025.
  • Foghorn Therapeutics' Gains from Investment Securities (Quarter) stood at $865000.0 in 2023, then plummeted by 94.57% to $47000.0 in 2024, then tumbled by 117.02% to -$8000.0 in 2025.
  • Its Gains from Investment Securities was -$8000.0 in Q2 2025, compared to $1.2 million in Q1 2025 and $47000.0 in Q4 2024.